Discover how Resolian supports early-career scientists like Jennifer Hawkins through opportunities at the REID Bioanalytical Forum. Learn about LC-MS/MS assay development and career growth in bioanalysis.
Our work, presented at APA 2025, focuses on developing an in vitro CES reaction phenotyping using p-nitrophenyl acetate (p-NPA) as a universal substrate. In this study, we compared different CES substrates, optimized the experimental conditions and developed an LC-MS method for simultaneous detection of p-NPA and its metabolites.
In today’s competitive drug development landscape, contract research organizations (CROs) face mounting pressure to deliver more than just scientific expertise. Success requires a multifaceted approach that combines global reach, consistent delivery, technological innovation, and unwavering client focus.
Did you know that you can start Phase I trials in Australia without an IND? That’s just one of several strategic benefits biotechs are leveraging to speed up development timelines and reduce costs – while generating globally accepted data.
In this article, we break it down.
What would you do if you found a piece of unidentified material in your toothpaste today? Would you use it? Would you throw the whole tube away? Or, would you send a complaint to the company..?
Foreign matter is an issue across all industries – from food to medicines and consumer products
🔬 How do you measure complex modality molecules at the lowest possible concentrations?
For modern therapies like antibody-drug conjugates (ADCs) and inhzlation drugs, precise bioanalysis at picogram levels is essential to ensure both efficacy and safety. At Resolian, we specialize in ultrasensitive assays that push the boundaries of detection.
Precision, efficiency, and scientific expertise are essential in today’s fast-moving bioanalytical landscape. At Resolian, we’ve taken a bold step forward—restructuring teams, refining method development processes, and strategically implementing automation to enhance service delivery.
Polymorph screening is a process that identifies and characterizes the crystalline forms of a compound, and then selects the best form for development.
Assessing and controlling the crystalline form of your material plays a crucial role in all the stages of the product lifecycle.
Foreign particulate matter (FPM) in vaccines poses risks to product safety, patient health, and regulatory compliance. With stringent guidelines from agencies like the FDA and EMA, identifying and controlling contaminants is essential to maintaining trust and ensuring safety.
Resolian is committed to reducing its environmental impact wherever feasibly possible.
Recently the Extractables and Leachables team at the Fordham lab of Analytical Sciences aimed to implement and evaluate green chemistry principles.
Chief Scientific Officer
Zhiyang Zhao, Ph.D., serves as Chief Scientific Officer (CSO) at Resolian. Dr. Zhao has over 30 years of pharmaceutical industry experience with special focus on drug metabolism and bioanalysis of small and large molecules in drug discovery and development. Dr. Zhao has previously held positions at Pfizer, GlaxoSmithKline, and Amgen. Before joining Resolian in 2015, Dr. Zhao served as Site Director of Preclinical Research at Amgen in Cambridge, Massachusetts, for over a decade.
Currently, Dr. Zhao serves as an Adjunct Professor at the Eshelman School of Pharmacy of the University of North Carolina at Chapel Hill, North Carolina, and as Editor-in-Chief of Drug Metabolism & Bioanalysis Letters, a journal by Bentham Science, which publishes in all areas of drug metabolism and bioanalysis. Dr. Zhao received his Ph.D. degree in Medicinal Chemistry from Virginia Polytechnic and State University (popularly known as Virginia Tech) in Blacksburg, Virginia.
Chief Executive Officer
Patrick Bennett has over 35 years of experience in pharmaceutical analysis and laboratory management. Now Chief Business Officer at Resolian, Patrick’s experience includes the roles of Strategic Marketing Director for Pharma with Thermo Fisher Scientific, LabCorp, and Vice President of Strategy and Development with PPD.
Patrick earned a B.S. degree in Toxicology and a M.S. degree in Pharmacology from the College of Pharmacy and Allied Health at St. John’s University and an M.B.A in International Marketing from the Martin J. Whitman School of Management at Syracuse University.